Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$3.68 - $59.40
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$5.91M
Enterprise Value-$5.57
Total Cash (Recent Filing)$14.53M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Aug 06, 2026EPS Estimate
-6.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-357.16
Shares Outstanding1,246,105
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-24.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase 1b AML Clinical DataRAINIER Phase 1b results showing very high response and remission rates materially de-risk mipletamig by evidencing deep, durable responses and a clean safety profile in frontline AML. Such durable clinical signals improve program credibility, accelerate dose selection and strengthen partner/commercial prospects over the medium term.
Radiopharmaceutical Collaboration Diversifies PipelineThe 50/50 Niowave partnership pairs Aptevo’s multispecific antibody platforms with Niowave’s isotope supply and reciprocal IP licensing, diversifying into targeted alpha/radiopharma. Equity alignment and supply access create durable development capacity and strategic differentiation in a constrained isotope ecosystem, enhancing long‑term program optionality.
Non-dilutive Grant Supports APVO451 DevelopmentThe ~$1.5M non-dilutive, milestone-tied grant funds APVO451 IND-enabling work and validates the trispecific nectin-4 strategy. This capital reduces near-term equity reliance, advances preclinical timelines toward IND candidacy, and provides independent program validation that can strengthen partnering discussions and de-risk development execution.
Bears Say
High And Persistent Cash BurnConsistently large negative operating and free cash flows (~-$27M TTM) indicate structural cash burn that will require repeated external financing. This ongoing outflow constrains the firm's ability to internally fund multiple programs, increases execution risk, and raises the probability of dilutive capital raises over the medium term.
No Recurring Revenue And Persistent LossesThe absence of recurring revenue and sustained operating losses (TTM net loss ≈ -$26.4M) mean the company lacks earnings capacity to self-sustain development. Reliance on milestone or partner payments yields unpredictable cash visibility and weakens negotiating leverage, leaving long‑term sustainability tied to clinical and partnership success.
Ongoing Financing/dilution Risk Despite Moderate LeverageAlthough debt levels are moderate (debt-to-equity ~0.38) and equity is positive, historical equity volatility and continued losses mean future capital needs will likely be met through dilutive financings or partner deals. That structural financing risk can dilute shareholders and limit strategic flexibility over the medium term.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $3.68 and its highest was $59.40 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $5.91M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$6.41 earnings per share for the quarter, missing the consensus estimate of -$5.6 by -$0.81.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -6.02.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,246,105 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$6.41 in its last earnings report, missing expectations of -$5.6. Following the earnings report the stock price went down -1.619%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(3342.62% Upside)
Technical Analysis
Ownership Overview
1.09% Insiders
1.79% Mutual Funds
<0.01% Other Institutional Investors
96.10% Public Companies and
Individual Investors